Iyo Cleveland Clinic yeUnited States Eric D. Wake et al. Yakataurwa kuti kuongororwa kwehutachiona T cell lymphoma (PTCL) muUnited States inosiyana zvakanyanya, uye kazhinji haina ruzivo rwakakosha rwe phenotypic kunyatso kusiyanisa lymphoma. Tichifunga nezve iri kuuya World Health Organisation kupatsanura, muyedzo wekuyedza mamaki akasarudzwa unofanirwa kuzadzwa. Kuongororwa kwechokwadi kuri kuwedzera kukosha, kuchatiunza munguva yekurapa kwePTCL. (Clin Lymphoma Myeloma Leuk. 2017; 17: 193-200.)
Nekudzika kwekunzwisisa kweiyo yakasarudzika yehuwandu hweparutivi T-cell lymphoma (PTCL), subtype-yakatarwa nzira dzekutsvagisa dzinoenderera mberi kubuda, uye kuongororwa kwechokwadi kunowedzera uye kwakanyanya kukosha.
Chidzidzo ichi chakawana dhata kubva kuongororo yezvekurapa zviyero zveparutivi T-cell lymphoma (KUKWANISA) uye kuitisa nzira yekuongorora kwevarwere vane histopathological kuongororwa kwePTCL. Chidzidzo CHAKAKWANA chiitiko chikuru chinotarisira boka revarwere vane PTCL nyowani muUnited States. Mhedzisiro yacho inoratidza kuti varwere ve499 vakanyoreswa kubva kumasangano makumi mana ezvidzidzo uye gumi nemashanu enzvimbo dzemunharaunda. Fomu rekutanga rekutarisa rakaunganidzwa mumatare e493, ayo mazana mana nemakumi matatu neshanu (435%) akawanikwa kuti aongororwe. Zvirwere zvinowanzozivikanwa ndeye PTCL, PTCL isina kutaurwa (PTCL-NOS), anaplastic yakakura cell lymphoma uye angioimmunoblastic T cell lymphoma (AITL). Mumwe murwere akaongorora avhareji ye88 (10-0) mamaki. CD21 inowanzoongororwa, asi kutaura kweCD30 hakuenderane nevarwere vasiri vaplastic yakakura cell lymphoma. Chete 30% yevarwere vane PTCL-NOS vakaongorora PD17 kutaura. CXCL1 chiratidzo chinotaridzika cheAITL. Izwi rekutaura kwevarwere veAITL i13%, asi chete 84% yevarwere vePTCL-NOS vakaona kutaura kweCXCL3. Mhedzisiro yekuongororwa kwevateveri vanobatsira T maseru mamaki akasiyana pakati pevarwere mumasangano ezvidzidzo nenharaunda. Masangano ezvidzidzo anowanzoongorora kutaura kwePD13 mune varwere vane AITL (1% vs 62%, P = 12).
